Annual Review of Cancer Biology

Toward Targeting Antiapoptotic MCL-1 for Cancer Therapy

Gemma L. Kelly\textsuperscript{1,2} and Andreas Strasser\textsuperscript{1,2}

\textsuperscript{1}The Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria 3052, Australia; email: gkelly@wehi.edu.au, strasser@wehi.edu.au

\textsuperscript{2}Department of Medical Biology, University of Melbourne, Melbourne, Victoria 3010, Australia

\textbf{Abstract}

Apoptosis is critical for embryonic development, tissue homeostasis, and the removal of infected or otherwise dangerous cells. It is controlled by three subgroups of the BCL-2 protein family—the BH3-only proteins that initiate cell death; the effectors of cell killing, BAX and BAK; and the anti-apoptotic guardians, including MCL-1 and BCL-2. Defects in apoptosis can promote tumorigenesis and render malignant cells refractory to anticancer therapeutics. Activation of cell death by inhibiting antiapoptotic BCL-2 family members has emerged as an attractive strategy for cancer therapy, with the BCL-2 inhibitor venetoclax leading the way. Large-scale cancer genome analyses have revealed frequent amplification of the locus encoding anti-apoptotic \textit{MCL-1} in human cancers, and functional studies have shown that MCL-1 is essential for the sustained survival and expansion of many types of tumor cells. Structural analysis and medicinal chemistry have led to the development of three distinct small-molecule inhibitors of MCL-1 that are currently undergoing clinical testing.

\textbf{Keywords}

apoptosis, BCL-2 protein family, MCL-1, BH3-only proteins, BAX/BAK apoptosis effectors, cancer therapy
INTRODUCTION

Apoptosis is a genetically programmed form of cell death that removes superfluous, damaged, or dangerous cells, such as those infected with pathogens or undergoing neoplastic transformation (Green 2019, Strasser et al. 2000). Accordingly, defects in apoptosis can promote tumorigenesis, particularly if they occur in conjunction with oncogenic lesions that drive aberrant cell division (Strasser et al. 1990, Vaux et al. 1988). Many cancers overexpress inhibitors of cell death or lack initiators of apoptosis, and these aberrations diminish the sensitivity of malignant cells to commonly used multitargeted anticancer agents, including targeted inhibitors of oncogenic kinases (Cragg et al. 2009, Strasser et al. 1991). Therefore, there has been great interest in developing drugs that can directly activate the apoptosis machinery for use in cancer therapy (Letai 2008, Merino et al. 2018). These so-called BH3-mimetics, small-molecule drugs that bind and inhibit select antiapoptotic BCL-2 family members, are emerging as promising new therapeutics for hematological and possibly also solid cancers, with the BCL-2-specific inhibitor venetoclax leading the way. Targeting the related antiapoptotic protein MCL-1 is of particular interest in the field because a substantial fraction of human cancers carry somatically acquired copy number amplifications of the genomic region containing its gene. Furthermore, functional investigations using inducible loss of Mcl-1 have revealed that the protein is critical for both the development and sustained survival and growth of diverse tumor cells. However, given that the (inducible) loss of MCL-1 also kills several vital normal cell types, such as cardiomyocytes (Thomas et al. 2013, Wang et al. 2013) and neurons (Arbour et al. 2008), there is concern that targeting MCL-1 for cancer therapy may not be safe. In this review, we describe the known functions of MCL-1 in nontransformed and malignant cells, and we discuss the development and ongoing preclinical testing of the first small-molecule inhibitors of MCL-1 (Caenepeel et al. 2018, Kotschy et al. 2016, Ramsey et al. 2018, Tron et al. 2018), in anticipation of the first disclosure of data from the clinical trials of these drugs.

THE APOPTOSIS MACHINERY IS CONTROLLED BY THE BCL-2 PROTEIN FAMILY

Apoptotic cell death is regulated by three subsets of proteins of the BCL-2 family (Figure 1) (Czabotar et al. 2014, Green 2019, Singh et al. 2019). The antiapoptotic proteins BCL-2, BCL-XL, MCL-1, BCL-W, and A1/BFL1 safeguard cell survival. The proapoptotic effectors BAX, BAK, and possibly BOK are essential for the execution of apoptosis by creating pores in the outer mitochondrial membrane, allowing apoptogenic factors such as cytochrome c and SMAC/DIABLO to be released into the cytosol, which then drive the demolition of the doomed cells (Green 2019). The proapoptotic BH3-only proteins—BIM, PUMA, BID, NOXA, BMF, BAD, BIK, and HRK—initiate apoptosis signaling. In surviving cells, the apoptosis effectors BAX and BAK are restrained by the antiapoptotic BCL-2 family members. Cell stress, such as that elicited by deprivation of nutrients or growth factors, activation of oncogenes, or treatment with chemotherapeutic drugs, causes transcriptional or posttranscriptional upregulation of BH3-only proteins, such as BIM or PUMA. These initiators of apoptosis bind with high affinity to the antiapoptotic BCL-2 family members, such as BCL-2 or MCL-1, and this liberates BAX and BAK to unleash the effector phase of apoptosis (Figure 1). Certain BH3-only proteins, such as BIM, BID, and PUMA, have been reported to also activate BAX and BAK by interacting with them directly (Figure 1). The interactions between members of the three subgroups of the BCL-2 protein family and hence the regulation of apoptosis are complex; for example, some BH3-only proteins (BIM, BID, and PUMA) can bind with high affinity to all antiapoptotic BCL-2 family members and are thus
The intrinsic apoptotic pathway is controlled by three groups of proteins, all belonging to the BCL-2 family of proteins. The proapoptotic BH3-only proteins are the initiators of cell death since they become upregulated in response to cytotoxic stimuli, including DNA damage, oncogene activation, and cytokine deprivation. They can bind and inhibit the antiapoptotic BCL-2 proteins, which are the guardians of cell survival. This leads to release and activation of the effectors of cell death, BAX and BAK, which can oligomerize and lead to mitochondrial outer membrane permeabilization (MOMP). Additionally, select BH3-only proteins have been reported to also directly activate BAX and BAK. Following MOMP, the release of apoptogenic factors activates caspases that mediate the demolition of the cell. Activation of BAX or BAK leading to MOMP is considered the point of no return in apoptosis signaling.

Different cellular stresses lead to upregulation of certain BH3-only proteins that then initiate apoptosis. For example, studies using knockout mice revealed that Puma and to a lesser extent Noxa, both direct transcriptional targets of the tumor suppressor p53, are critical for the killing of cells by DNA damage–inducing drugs (Figure 1) (Jeffers et al. 2003, Villunger et al. 2003). Conversely, Bim is needed for cell killing induced by nutrient/growth factor deprivation, glucocorticoids, ER stress, or inhibitors of oncogenic kinases (Bouillet et al. 1999, Kuroda et al. 2006, Puthalakath et al. 2007). The apoptosis effectors BAX and BAK have largely overlapping functions; accordingly, mice lacking either Bax or Bak have only minor defects, whereas Bax/Bak double-knockout and Bax/Bak/Bok triple-knockout mice have significant developmental abnormalities and their cells are highly resistant to all apoptotic stimuli tested (Ke et al. 2018, Lindsten et al. 2000). Thus, activation of BAX or BAK (or maybe BOK) constitutes the point of no return in apoptotic cell death signaling.

CONTROL OF MCL-1 EXPRESSION

The expression of MCL-1 and the other antiapoptotic BCL-2 family proteins is controlled at several levels, permitting tight control over cell fate. The expression of the genes that encode the antiapoptotic BCL-2 family proteins can be transcriptionally upregulated in response to cellular...
Figure 2
(a) Specificities of different BH3-only proteins for the different antiapoptotic BCL-2 family proteins. (b) Specificities of different BH3-mimetic drugs for the different antiapoptotic BCL-2 family proteins. (c) Mode of action of an MCL-1-specific BH3-mimetic drug to kill cells. The MCL-1 inhibitor can bind to MCL-1, preventing it from binding to BAX and BAK and causing displacement of BH3-only proteins such as BIM from MCL-1, allowing BIM to bind to and inhibit other antiapoptotic BCL-2 proteins present in the cell (that are not targeted by the MCL-1 inhibitor), such as BCL-2 and BCL-XL. Overall, these events unleash BAX and BAK from the restraint of MCL-1 and the other antiapoptotic BCL-2 family members present in the cell, allowing them to be activated and oligomerize, forming holes in the outer mitochondrial membrane and initiating the caspase cascade that demolishes the cell.

Erratum
stimulation with a broad range of growth factors (e.g., IL-3, IL-5, VEGF, SCF) and downregulated following growth factor withdrawal in a cell-type-dependent manner (Chao et al. 1998, Huang et al. 2000, Le Gouill et al. 2004, Wang et al. 2003). Several cellular transcriptional pathways are capable of regulating MCL-1 expression, including the JAK/STAT, PI3K/AKT, MEK/ERK, and p38/MAPK pathways (Akgul et al. 2000, Wang et al. 2003). Select microRNAs (miRs) are reported to posttranscriptionally regulate expression of antiapoptotic BCL-2 family members (reviewed by Villanova et al. 2018); for example, MCL-1 transcripts are targeted by miR-29b and miR-125b (Gong et al. 2013, Mott et al. 2007). An additional level of control over the expression and function of the antiapoptotic BCL-2 family proteins is exerted at the posttranslational level. The stability of the MCL-1 protein can be controlled by polyubiquitin ligases, including MULE (MCL-1 ubiquitin ligase E3), SCF^[bub7]$, and SCF^[R-TicP]$, that target it for proteasomal degradation (Ding et al. 2007, Inuzuka et al. 2011, Warr et al. 2005, Zhong et al. 2005), and this is counteracted by the deubiquitinases USP9X and USP13 that can stabilize MCL-1 protein expression (Schwickart et al. 2010, Zhang et al. 2018). Phosphorylation of MCL-1 at residues within the PEST domain by protein kinases, such as GSK-3, can also affect the stability of MCL-1 (reviewed by Thomas et al. 2010).
DIFFERENT ANTIAPOPTOTIC BCL-2 FAMILY MEMBERS ARE CRITICAL TO SAFEGUARD DISTINCT CELL TYPES

Studies using whole-body and tissue-restricted knockout of genes in mice have identified overlapping roles of the different antiapoptotic Bcl-2 family members in the survival of certain cell types. Bcl-2 is critical for the survival of progenitor cells in the embryonic kidney, melanocyte progenitors, and mature B and T lymphocytes (Bouillet et al. 2001, Veis et al. 1993). Bcl-xL is required for the survival of erythroid progenitors (both in embryos and adults), certain neuronal populations, and platelets and lymphoid cells at select stages of differentiation and activation (Mason et al. 2007, Motoyama et al. 1995, Wagner et al. 2000). Of all the antiapoptotic Bcl-2 family members, the loss of Mcl-1 has the most dramatic impact. Constitutive loss of Mcl-1 in all tissues causes embryonic lethality prior to implantation (embryonic day 3.5) (Rinkenberger et al. 2000), and conditional deletion of Mcl-1 was shown to deplete hematopoietic stem/progenitor cells (Opferman et al. 2005), B cell–committed and T cell–committed progenitors (Opferman et al. 2003), activated B cells (Vikstrom et al. 2010), antibody-secreting plasma cells (Peperzak et al. 2013), neuronal cells (Arbou et al. 2008) and cardiomyocytes (Thomas et al. 2013, Wang et al. 2013). The dramatic impact of the genetic loss of Mcl-1 on so many cell types has raised significant concerns with regard to targeting this antiapoptotic protein for cancer therapy. Much less severe defects were observed following the loss of some other antiapoptotic Bcl-2 proteins. Bcl-w loss only causes defects in spermatogenesis (Print et al. 1998), and so far no defects have been reported for mice deficient for A1 (Schenk et al. 2017).

Studies using cells in which two antiapoptotic Bcl-2 family members were inactivated, either through genetic deletion in mice or using targeted inhibitors on cultured cells (see below), revealed that these proteins can have substantially overlapping functions in the survival of many cell types. For example, the combined hepatocyte-restricted loss of Mcl-1 and Bcl-x causes considerably greater liver damage in mice than loss of either antiapoptotic gene alone (Hikita et al. 2009). Moreover, BH3-mimetic drug–mediated inhibition of Mcl-1, Bcl-2, and Bcl-xL impaired the survival in culture of B and T lymphoid cells and certain myeloid cell populations to a greater extent than inhibition of only one or two of these proteins (Vikstrom et al. 2016). In at least certain cell types, there appears to be a delicate balance between survival and death. For example, the combined loss of only one allele of Mcl-1 with one allele of Bcl-x causes severe craniofacial abnormalities during mouse embryonic development, and remarkably, these defects can be prevented by the additional loss of one allele of the proapoptotic BH3-only gene Bim (Grabow et al. 2018). The above studies highlight the impact of perturbations in apoptosis on the survival of normal cells of diverse cellular types, and in particular, they underscore the necessity of Mcl-1 expression for the survival of many normal cell types, which may affect the use of MCL-1-inhibiting drugs for cancer therapy.

ABERRANT EXPRESSION OF MCL-1 AND OTHER ANTIAPOPTOTIC BCL-2 FAMILY MEMBERS IN HUMAN CANCER

BCL-2, the first regulator of programmed cell death to be recognized in any organism (Vaux et al. 1988), was discovered owing to the chromosomal translocation of its gene into the IGH (immunoglobulin heavy chain) locus (t[14;18]), with consequent deregulated overexpression of BCL-2 in almost all cases of human follicular center B cell lymphoma (Tsujimoto et al. 1984). Chromosomal translocations involving the genes encoding other prosurvival BCL-2 proteins have not been reported, but somatically acquired copy number amplifications of the genomic regions containing the MCL-1 or BCL-X gene have been found in ~10% or ~3% of human cancers overall, respectively (Beroukhim et al. 2010), and these amplifications were also apparent...
in TCGA (The Cancer Genome Atlas) data through cBioPortal (Cerami et al. 2012) and in data summarized by Campbell & Tait (2018). For a small number of cell lines with such somatically acquired gene copy number amplifications, it was shown that knockdown of MCL-1 or BCL-XL using RNA interference technology can induce apoptosis and curtail their growth in culture. This provides evidence that it is specifically the increase in expression of these antiapoptotic proteins, as opposed to the gain of another protein encoded by a gene residing within the amplified region of the genome, that contributed to neoplastic transformation and malignant growth (Beroukhim et al. 2010). Notably, genetic loss or epigenetic silencing of genes encoding proapoptotic BCL-2 family members has also been observed in diverse cancers, including loss of BIM in mantle cell B lymphoma (Tagawa et al. 2005) and renal cell carcinoma (Zantl et al. 2007) or loss of BAX in DNA mismatch repair-defective colon cancer (Rampino et al. 1997). Collectively, these findings show that defects in apoptosis caused by deregulated overexpression of antiapoptotic BCL-2 family members or abnormally reduced expression of their proapoptotic relatives are present in a substantial fraction of cancers of diverse origins.

IMPACT OF GENETIC LOSS OF MCL-1 OR OTHER ANTIAPOPTOTIC BCL-2 FAMILY MEMBERS ON TUMOR DEVELOPMENT

Very early in cell death research it was established that abnormal overexpression of Bcl-2 (Strasser et al. 1990, Vaux et al. 1988) or its antiapoptotic family members such as Mcl-1 (Campbell et al. 2010) can promote tumorigenesis. However, the importance of antiapoptotic BCL-2 proteins when expressed under normal endogenous control in tumor development remained an open question. Bcl-2 overexpression greatly accelerates lymphoma development driven by deregulated expression of the oncogene c-Myc, which promotes cell proliferation and metabolism (Soucek & Evan 2010). However, this was not predictive of a role for endogenously expressed Bcl-2 in the development of c-Myc-driven lymphomas, since homozygous loss of Bcl-2 had no impact on tumor incidence or latency (Kelly et al. 2007). By contrast, loss of just a single allele of Mcl-1 could almost completely abrogate c-Myc-driven lymphomagenesis (Grabow et al. 2016). Endogenous Bcl-xL expression could also contribute to c-Myc-driven lymphoma development but to a lesser extent than Mcl-1 since complete loss of Bcl-xL was required to inhibit c-Myc-driven lymphoma development and loss of only one allele of Bcl-x had no impact (Kelly et al. 2011). This indicates that Mcl-1 is more important for the development of these tumors than Bcl-xL. Importantly, c-Myc-driven lymphoma development could be restored in mice lacking one allele of Mcl-1 or in those completely deficient for Bcl-x by concomitant loss of just a single allele of proapoptotic Bim and to a lesser extent by loss of Puma (Delbridge et al. 2015, Grabow et al. 2016). This reveals that a major role of Mcl-1 in c-Myc-driven lymphomagenesis (and possibly in the development of tumors of other cell lineages and of tumors driven by other oncogenes) must be to safeguard the survival of cells during early stages of their neoplastic transformation when the stresses emanating from the activation of oncogenes cause an increase in the levels of apoptosis-initiating BH3-only proteins. Additional experiments using transgenic mice or retroviruses to express various oncogenes in mice revealed that Mcl-1 (expressed under its normal endogenous control) is also critical for the development of thymic T cell lymphoma driven by loss of p53 (Grabow et al. 2014) or gain-of-function mutations in Notch (Spinner et al. 2016), BCR-ABL-driven pre-B cell acute lymphocytic leukemia (pre-B ALL), and acute myeloid leukemia (AML) driven by MLL-AF9, AML-ETO, or certain other oncogenic fusion proteins (Glaser et al. 2012). There is increasing evidence that MCL-1 expression is also required for the development of certain solid cancers, including a mouse model of breast cancer where there was strong selection to retain Mcl-1 expression (Campbell et al. 2018). Collectively, these findings demonstrate a critical role for MCL-1
in the development of several types of cancers with a variety of oncogenic drivers. However, it will be of interest to expand these investigations, with a particular focus on the role of MCL-1 and its antiapoptotic relatives in an extended panel of solid cancer types.

**IMPACT OF INDUCIBLE LOSS OF MCL-1 OR OTHER ANTIAPOPTOTIC BCL-2 FAMILY MEMBERS ON SUSTAINED TUMOR GROWTH**

While the above-described studies helped identify the roles of MCL-1 and related proteins in the development of tumors, they provided no direct insight into the more clinically relevant questions concerning which antiapoptotic BCL-2 family member is critical for the sustained survival and growth of a given cancer and therefore which is a potentially attractive therapeutic target. These questions were addressed using several methods to reduce or abrogate expression of distinct antiapoptotic BCL-2 family members within tumor cells. The tools and resources used include (a) genetically engineered mouse tumor models in which *loxP*-flanked antiapoptotic *Bcl-2* family genes (*Mcl-1*, *Bcl-x*, and *Bcl-2*) can be deleted at will using a tamoxifen-regulatable Cre recombinase (*CreER*), (b) inducible expression of short hairpin RNA vectors targeting a particular antiapoptotic gene, and (c) inducible expression of BH3-only proteins (initiators of apoptosis) or variants thereof that bind and inhibit select antiapoptotic BCL-2 family members (Figure 2a). The loss or inhibition of BCL-XL or BCL-2 inhibited the survival and expansion of certain tumor-derived cell lines [e.g., the impact of targeting BCL-XL in certain cell lines derived from multiple myeloma, AML, or melanoma (Gong et al. 2016, Lee et al. 2019, Pan et al. 2014)]. However, the loss or inhibition of MCL-1 had by far the greatest impact on the sustained growth and survival of several cancers, including AML driven by several oncogenic fusion proteins (e.g., MLL-ENL, MLL-AF9, AML-Eto9a) (Glaser et al. 2012), BCR-ABL-driven pre-B ALL (Koss et al. 2013), c-Myc-driven pre-B or B cell lymphoma (Kelly et al. 2014), T cell lymphoma driven by loss of p53 (Grabow et al. 2014) or mutations in Notch (Spinner et al. 2016), multiple myeloma (Gong et al. 2016), and melanoma (Lee et al. 2019). In several of these studies, loss of *Mcl-1* was shown to markedly delay or even abrogate tumor growth within mice (e.g., Glaser et al. 2012, Kelly et al. 2014, Koss et al. 2013). Remarkably, in the case of c-Myc-driven pre-B or B cell lymphoma, the loss of just a single allele of *Mcl-1* was sufficient to cure mice of these tumors, unless they had acquired a mutation in the tumor suppressor p53 (Kelly et al. 2014). This was a very important discovery considering earlier studies examining the impact of loss of *Mcl-1* on normal cells that showed that severe defects followed loss of both alleles of *Mcl-1* in normal tissues (see above) but that loss of a single allele of *Mcl-1* was tolerable for normal cells (Brinkmann et al. 2017, Rinkenberger et al. 2000). Accordingly, these observations provided hope that a therapeutic window might be established for drugs that inhibit MCL-1. Collectively, these findings provided evidence that targeting MCL-1 with a small-molecule inhibitor might be efficacious and tolerable for cancer therapy.

**DEVELOPMENT AND TESTING OF MCL-1-SPECIFIC BH3-MIMETIC DRUGS**

The finding that proapoptotic BH3-only proteins that initiate apoptosis signaling are the natural inhibitors of MCL-1 and the other antiapoptotic BCL-2 family members (Huang & Strasser 2000) led to the idea that apoptosis could be induced in tumor cells by small-molecule compounds that could mimic the action of the BH3-only proteins, i.e., so-called BH3-mimetic drugs (Figure 2b). Developing such drugs has been challenging because of the requirement for these BH3-mimetics to disrupt protein-protein interactions. The first bona fide BH3-mimetic
compound to be published was ABT-737, which potently binds to and inhibits BCL-2, BCL-XL, and BCL-W (Oltersdorf et al. 2005). This compound could potently kill certain cancer-derived cell lines (leukemia, lymphoma, and lung and colon cancer) either as a single agent or when used in combination with other anticancer agents in culture or within tumor-grafted mice. Of note, ABT-737 was efficacious for several more tumor-derived cell lines when used in combination with standard-of-care anticancer agents (Oltersdorf et al. 2005). A related compound that also inhibits BCL-2, BCL-XL, and BCL-W (Figure 2b), ABT-263, was the first BH3-mimetic drug to progress to clinical trials (Roberts et al. 2012, Wilson et al. 2010). Although ABT-263 had a marked impact in patients with chronic lymphocytic leukemia (CLL), a BCL-2-dependent cancer, its progression in the clinic is hampered by its on-target toxicity to platelets, which require BCL-XL for their survival (Mason et al. 2007). This prompted the development of the BCL-2-specific BH3-mimetic drug ABT-199, also called venetoclax or venclexta (Figure 2b), which is well tolerated in patients and due to its remarkable efficacy has been approved in several countries for the treatment of refractory CLL (Roberts et al. 2016, Souers et al. 2013) and AML (Konopleva et al. 2016, Vo et al. 2012). This drug is currently in ~50 clinical trials as a single agent or in combination with additional anticancer drugs (e.g., BTK inhibitors or CD20 antibodies) for several hematopoietic malignancies and breast cancer (reviewed by Merino et al. 2018).

The success of venetoclax, combined with the compelling preclinical results presented in the abovementioned publications and many others, encouraged pharmaceutical and biotechnology companies and academic institutions to develop inhibitors of MCL-1 for cancer therapy. The first compounds to be published, A-1210477 and the series of MCL-1 inhibitors developed by the Fesik laboratory, bound MCL-1 with ~100-nM affinity but had limited potency in killing tumor-derived cell lines in culture (in part due to substantial binding to serum proteins and relatively poor membrane permeability); no results regarding in vivo efficacy were reported for these compounds (Friberg et al. 2013, Leverson et al. 2015). In contrast, the tool compound S63845 developed by Servier binds to MCL-1 with an ~1-nM (or higher) affinity (Figure 2b), has good membrane permeability, and has low binding to serum proteins (Kotschy et al. 2016). Accordingly, this compound can effectively kill a broad range of cancer-derived cell lines as a single agent in culture. This included many human multiple myeloma and AML cell lines, where sensitivity did not correlate with the genetic lesion (e.g., chromosomal translocation) driving their neoplastic transformation, as well as some B and T cell lymphoma lines (Kotschy et al. 2016). For all cell lines tested, the clearest predictor was an inverse correlation between the levels of BCL-X mRNA and sensitivity to S63845 (Kotschy et al. 2016). Remarkably, treatment with S63845 substantially delayed the growth of human multiple myeloma- or AML-derived cell lines in immune-deficient mice and could cure ~70% of immune-competent mice bearing c-Myc-driven mouse lymphomas (Kotschy et al. 2016). Of note, doses of S63845 that were effective at inhibiting tumor growth in mice were readily tolerated, with no overt damage seen in tissues in which the genetic (complete) loss of Mcl-1 causes severe and often fatal pathology (Kotschy et al. 2016). This may be explained by the fact that treatment with an inhibitor for a limited amount of time does not have as much of an impact as complete irreversible loss of this antiapoptotic protein in genetic studies.

Amgen recently published their own inhibitors of MCL-1: the clinical compound AMG-176 and the related analog compound AM-8621, which also have very high affinity for their target (Figure 2b), good membrane permeability, and low serum binding (Caenepeel et al. 2018). Accordingly, AM-8621 also showed excellent on-target activity in a broad panel of hematological cancer–derived cell lines in culture, and for some cancer–derived lines, this was also documented using AMG-176 in vivo in tumor xenograft studies (Caenepeel et al. 2018). Similarly, two other MCL-1 inhibitors, AZD5991 from AstraZeneca and VU661013, recently demonstrated efficacy toward hematological cancer cell lines (Tron et al. 2018) and AML cell lines (Ramsey et al. 2018),
respectively, both in vitro and in vivo (Figure 2b). The MCL-1 inhibitors S63845, AM-8621, and AZD5991 had only modest impact as single agents against a broad panel of solid cancer–derived cell lines (including ones derived from breast, colon, and lung cancers and melanomas). However, S63845, AM-8621, and AMG-176 synergized potently with inhibitors of oncogenic kinases (e.g., inhibitors of MEK, EGFR, or BRAF) in killing a collection of solid cancer–derived cell lines in culture and in vivo in tumor xenograft studies (Caenepeel et al. 2018, Kotschy et al. 2016, Nangia et al. 2018).

S63845, AMG-176, and AZD5991 have considerably higher (∼6- to 1000-fold) affinity for human MCL-1 than mouse Mcl-1. Thus, testing these drugs using mouse tumor–derived cell lines or regular mice may underestimate their efficacy and, perhaps more importantly, their on-target toxicity. To overcome these limitations, two groups independently generated mice in which the coding regions for mouse Mcl-1 were replaced with those for human MCL-1 (huMcl-1 mice). Initial experiments conducted in huMcl-1 mice bearing tumors expressing human MCL-1 reaffirmed that a therapeutic window could be established for these two MCL-1 inhibitors, even in combination with the commonly used chemotherapeutic agent cyclophosphamide (Brennan et al. 2018, Caenepeel et al. 2018). Collectively, the results from these extensive preclinical tests supported the entry of three MCL-1 inhibitors—S64315/MIK-665 from Servier and Novartis, AMG-176 from Amgen, and AZD5991 from AstraZeneca—into clinical trials (Table 1 summarizes the ongoing clinical trials with these drugs). An alternative approach to targeting MCL-1 for cancer therapy would be to use PROTAC-like degraders of MCL-1 protein; however, these are currently in an earlier stage of development than BH3-mimetic drugs (Papatzimas et al. 2019).

Table 1  Summary of the current clinical trials using MCL-1 inhibitor drugs

| ClinicalTrials.gov identifier | Clinical trial phase | MCL-1 inhibitor | Sponsor | Combination drugs | Malignancies |
|------------------------------|----------------------|-----------------|---------|-------------------|--------------|
| NCT02675452                  | Phase I              | AMG-176         | Amgen   | N/A               | Relapsed or refractory multiple myeloma or acute myeloid leukemia |
| NCT02979366                  | Phase I              | S64315 (also referred to as MIK-665) | Servier | N/A               | Acute myeloid leukemia, myelodysplastic syndrome |
| NCT02992483                  | Phase I              | MIK-665 (also referred to as S64315) | Novartis | N/A               | Refractory or relapsed multiple myeloma or lymphoma |
| NCT03218683                  | Phase I              | AZD5991         | AstraZeneca | N/A               | Relapsed or refractory hematologic malignancies: non-Hodgkin’s lymphoma, Richter syndrome, chronic lymphocytic leukemia, small lymphocytic leukemia, T cell lymphoma, multiple myeloma |
| NCT03672695                  | Phase I              | S64315 (also referred to as MIK-665) | Servier | Venetoclax (BCL-2 inhibitor) | Acute myeloid leukemia |
| NCT03797261                  | Phase I              | AMG-176         | AbbVie  | Venetoclax (BCL-2 inhibitor) | Relapsed or refractory acute myeloid leukemia or non-Hodgkin’s lymphoma/diffuse large B cell lymphoma |

*In November 2019, the US Food and Drug Administration put a temporary hold on clinical trials of MCL-1 inhibitors.*
MECHANISMS BY WHICH MCL-1-SPECIFIC BH3-MIMETIC DRUGS KILL CANCER CELLS

MCL-1 promotes the survival of cells by restraining BAX and BAK (see above; Figure 1). Therefore, its inhibition by a BH3-mimetic drug or its genetic loss is predicted to kill cells by activating BAX/BAK-mediated apoptosis. As predicted, the combined loss of BAX and BAK, using CRISPR/Cas9 technology, rendered all tumor-derived cell lines tested fully resistant to the MCL-1 inhibitors S63845 (Kotschy et al. 2016) and AMG-176 (Caenepeel et al. 2018). However, simple prevention of MCL-1-mediated restraint of BAX/BAK probably does not fully account for the mechanism of tumor cell killing by the MCL-1-specific BH3-mimetic drugs. Genetic and biochemical studies revealed that liberating BH3-only proteins (particularly BIM and NOXA) from MCL-1, thus allowing them to bind to and inhibit the other antiapoptotic BCL-2 family members present in a tumor cell, also contributes to these drugs’ mechanism of action (Figure 2c) (Nangia et al. 2018). This is consistent with the notion that for BAX or BAK to become activated to unleash the effector phase of apoptosis, all antiapoptotic proteins present within a cell must be inhibited. This also explains why in tumor cells that express readily detectable amounts of two (or more) antiapoptotic BCL-2 family members, treatment with a BH3-mimetic drug that targets only one of them is usually insufficient to cause substantial killing. Achieving efficient killing requires treating such cells with, for example, two BH3-mimetic drugs to target MCL-1 plus BCL-2 (Caenepeel et al. 2018, Kotschy et al. 2016, Moujalled et al. 2019, Tron et al. 2018) or a single-BH3-mimetic drug in combination with an additional anticancer agent (e.g., cyclophosphamide or inhibitors of oncogenic kinases; see above) (Kotschy et al. 2016, Nangia et al. 2018); these other anticancer agents cause an increase in BH3-only proteins (particularly, BIM, PUMA, and NOXA) that can inhibit the antiapoptotic BCL-2 family members that are not targeted by the BH3-mimetic drug used (Figure 2).

In addition to inhibiting apoptosis, MCL-1 also promotes energy production by acting in the intermitochondrial space (Perciavalle et al. 2012). It is therefore conceivable that treatment with MCL-1-specific BH3-mimetic drugs or genetic loss of Mcl-1 can inhibit the survival and growth of malignant (and nontransformed) cells not only by inducing BAX/BAK-mediated apoptosis but also by impairing energy production in mitochondria. However, the loss of the BH3-only protein BIM or the combined loss of the apoptosis effectors BAX and BAK was shown to render cell lines derived from AML, multiple myeloma, pre-B/B cell lymphoma, or certain other tumors fully resistant to the induced complete genetic deletion of Mcl-1 or treatment with MCL-1-specific BH3-mimetic drugs (Caenepeel et al. 2018, Glaser et al. 2012, Gong et al. 2016, Kotschy et al. 2016). This indicates that, at least in malignant cells, genetic loss of Mcl-1 or inhibition of MCL-1 mediated by BH3-mimetic drugs impairs survival and growth solely by unleashing apoptosis. Whether this is also the case in normal cells remains to be fully determined, and answering this question is very important for predicting and managing on-target toxicities of MCL-1-specific BH3-mimetic drugs for healthy tissues. Studies have sought to address this using Bak-deficient mice, where either Mcl-1 alone or Mcl-1 plus Bax were inducibly genetically deleted in cardiomyocytes using a tissue-restricted tamoxifen-activatable Cre recombinase. Deletion of Mcl-1 in Bak-deficient cardiomyocytes led to substantial death and fatal damage to the heart. Combined inducible deletion of Mcl-1 and Bax on the Bak−/− background caused less, but still marked, damage to the heart (Thomas et al. 2013, Wang et al. 2013). It was therefore concluded that the genetic loss of Mcl-1 caused damage to the heart not only by unleashing Bax/Bak-mediated apoptosis in cardiomyocytes but also through additional mechanisms. However, when interpreting these findings, it is important to bear in mind that Mcl-1 protein has a very short half-life (20–30 min) whereas Bax protein has a long half-life (~20 h). Therefore, with inducible CRE-mediated deletion of both Mcl-1 and
Bax, cardiomyocytes will experience a time when they completely lack Mcl-1 protein but still contain substantial Bax protein. Thus, the incomplete protection of cardiomyocytes observed could be due to the induction of apoptosis through the residual Bax present in these cells early after inducible genetic deletion of Mcl-1 and Bax. This is an important issue to resolve and could be done by sequential genetic removal of Bax before Mcl-1 on a Bak−/− background using two gene recombination systems (e.g., FLP and CRE recombinases). Perhaps even more importantly, researchers need to understand in detail the dose-limiting toxicities of MCL-1-specific BH3-mimetic drugs and the mechanisms causing them to make progress with these drugs in the clinic.

CONCLUSIONS AND PERSPECTIVES

Following the success of the BCL-2 inhibitor venetoclax in the clinic (Roberts et al. 2016, Souers et al. 2013), MCL-1 inhibitors have been the latest BH3-mimetics to enter into clinical trials. Information on the potential of these drugs as anticancer agents is eagerly awaited and will emerge as the clinical trials progress. From preclinical work it is predicted that these MCL-1 inhibitors will have the most impact and benefit across diverse tumor types when used in combination with other therapeutics, perhaps including BH3-mimetics targeting other antiapoptotic BCL-2 proteins (e.g., venetoclax to inhibit BCL-2), chemotherapeutic agents that induce expression of the proapoptotic BH3-only proteins, or drugs that target the oncogenic drivers of tumor cell proliferation. Future efforts will therefore need to focus on testing the efficacy and tolerability of rational drug combinations in tumor models, ideally using huMcl-1 mice to overcome the issues of preferential binding of these drugs to human MCL-1 versus mouse Mcl-1. Additionally, to date there are very few identified markers of response or resistance to MCL-1 inhibitors and other BH3-mimetic drugs. The identification of prognostic indicators that could be used to stratify patients would therefore likely improve the clinical application of this exciting emerging class of anticancer agents.

DISCLOSURE STATEMENT

The Walter and Eliza Hall Institute receives milestone and royalty payments related to venetoclax, and employees (A.S. and G.L.K.) may be eligible for benefits related to these payments. The laboratories of A.S. and G.L.K. receive research funding from Servier.

ACKNOWLEDGMENTS

We thank all members of the Blood Cells and Blood Cancer Division at The Walter and Eliza Hall Institute (WEHI) for their helpful and insightful discussions and E. Conti from the WEHI Graphics Department for assistance with preparing figures. Our laboratory receives research funding from the Victorian Cancer Agency Fellowship (MCRF 17028) awarded to G.L.K.; Cancer Council Victoria, grants-in-aid #1086157 and #1147328 awarded to G.L.K.; the National Health and Medical Research Council, project grant #1086291 awarded to G.L.K. and program grant #101671 awarded to A.S.; fellowship #1020363 awarded to A.S.; the Leukaemia Foundation Australia grant awarded to G.L.K. and A.S.; the Leukaemia and Lymphoma Society grant #7001-13 awarded to A.S.; the estate of Anthony (Toni) Redstone OAM and The Craig Perkins Cancer Research Foundation; and operational infrastructure grants through the Australian NHMRC (National Health and Medical Research Council) IRIISS (Independent Research Institute Infrastructure Support Scheme) and the Victorian State Government Operational Infrastructure Support.
LITERATURE CITED

Akgul C, Turner PC, White MR, Edwards SW. 2000. Functional analysis of the human MCL-1 gene. Cell Mol Life Sci 57:684–91

Arbour N, Vanderluit JL, Le Grand JN, Jahani-Asl A, Ruzhynsky VA, et al. 2008. Mcl-1 is a key regulator of apoptosis during CNS development and after DNA damage. J. Neurosci. 28:6068–78

Beroukhim R, Mermel C, Porter D, Wei G, Raychaudhuri S, et al. 2010. The landscape of somatic copy-number alteration across human cancers. Nature 463:899–905

Bouillet P, Cory S, Zhang L-C, Strasser A, Adams JM. 2001. Degenerative disorders caused by Bcl-2 deficiency are prevented by loss of its BH3-only antagonist Bim. Dev. Cell 1:645–53

Bouillet P, Metcalf D, Huang DC, Tarlinton DM, Kay TW, et al. 1999. Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity. Science 286:1735–38

Brennan MS, Chang C, Tai L, Lessene G, Strasser A, et al. 2018. Humanized McI-1 mice enable accurate preclinical evaluation of MCL-1 inhibitors destined for clinical use. Blood 132:1573–83

Brinkmann K, Grabow S, Hyland CD, Teh CE, Alexander WS, et al. 2017. The combination of reduced MCL-1 and standard chemotherapeutics is tolerable in mice. Cell Death Differ. 24:2032–43

Caenepeel S, Brown SP, Belmontes B, Moody G, Keegan KS, et al. 2018. AMG 176, a selective MCL1 inhibitor, is effective in hematologic cancer models alone and in combination with established therapies. Cancer Discov. 8:1582–97

Campbell KJ, Bath ML, Turner ML, Vandenberg CJ, Bouillet P, et al. 2010. Elevated Mcl-1 perturbs lymphopoiesis, promotes transformation of hematopoietic stem/progenitor cells, and enhances drug resistance. Blood 116:3197–207

Campbell KJ, Dhayade S, Ferrari N, Sims AH, Johnson E, et al. 2018. MCL-1 is a prognostic indicator and drug target in breast cancer. Cell Death Dis. 9:19

Campbell KJ, Tait SWG. 2018. Targeting BCL-2 regulated apoptosis in cancer. Open Biol. 8:180002

Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, et al. 2012. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2:401–4

Chao J-R, Wang J-M, Lee S-F, Peng H-W, Lin Y-H, et al. 1998. mcl-1 is an immediate-early gene activated by the granulocyte-macrophage colony-stimulating factor (GM-CSF) signaling pathway and is one component of the GM-CSF viability response. Mol. Cell. Biol. 18:4883–98

Chen L, Willis SN, Wei A, Smith BJ, Fletcher JJ, et al. 2005. Differential targeting of pro-survival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol. Cell 17:393–403

Cragg MS, Harris C, Strasser A, Scott CL. 2009. Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics. Nat. Rev. Cancer 9:321–26

Czabotar PE, Lessene G, Strasser A, Adams JM. 2014. Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat. Rev. Mol. Cell Biol. 15:49–63

Delbridge AR, Grabow S, Bouillet P, Adams JM, Strasser A. 2015. Functional antagonism between pro-apoptotic BIM and anti-apoptotic BCL-XL in MYC-induced lymphomagenesis. Oncogene 34:1872–76

Ding Q, He X, Hsu JM, Xia W, Chen CT, et al. 2007. Degradation of Mcl-1 by β-TrCP mediates glycogen synthase kinase 3-induced tumor suppression and chemosensitization. Mol. Cell. Biol. 27:4006–17

Friberg A, Vigil D, Zhao B, Daniels RN, Burke JP, et al. 2013. Discovery of potent myeloid cell leukemia 1 (Mcl-1) inhibitors using fragment-based methods and structure-based design. J. Med. Chem. 56:15–30

Glaser S, Lee EF, Trounson E, Bouillet P, Wei A, et al. 2012. Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia. Genes Dev. 26:120–25

Gong J, Zhang JP, Li B, Zeng C, You K, et al. 2013. MicroRNA-125b promotes apoptosis by regulating the expression of Mcl-1, Bcl-w and IL-6R. Oncogene 32:3071–79

Gong JN, Khong T, Segal D, Yao Y, Riffkin CD, et al. 2016. Hierarchy for targeting prosurvival BCL2 family proteins in multiple myeloma: pivotal role of MCL1. Blood 128:1834–44

Grabow S, Delbridge AR, Aubrey BJ, Vandenberg CJ, Strasser A. 2016. Loss of a single Mcl-1 allele inhibits MYC-driven lymphomagenesis by sensitizing pro-B cells to apoptosis. Cell Rep. 14:2337–47
Grabow S, Delbridge AR, Valente LJ, Strasser A. 2014. MCL-1 but not BCL-XL is critical for the development and sustained expansion of thymic lymphoma in p53-deficient mice. *Blood* 124:3939–46

Grabow S, Kueh AJ, Ke F, Vanyai HK, Sheikh BN, et al. 2018. Subtle changes in the levels of BCL-2 proteins cause severe craniofacial abnormalities. *Cell Rep.* 24:3285–95.e4

Green DR. 2019. The coming decade of cell death research: five riddles. *Cell* 177:1094–107

Hikita H, Takehara T, Shimizu S, Kodama T, Li W, et al. 2009. Mcl-1 and Bcl-xL cooperatively maintain integrity of hepatocytes in developing and adult murine liver. *Hepatology* 50:1217–26

Huang DCS, Strasser A. 2000. BH3-only proteins—essential initiators of apoptotic cell death. *Cell* 103:839–42

Huang HM, Huang CJ, Yen JJ. 2000. Mcl-1 is a common target of stem cell factor and interleukin-5 for apoptosis prevention activity via MEK/MAPK and PI-3K/Akt pathways. *Blood* 96:1764–71

Inuzuka H, Shaik S, Onoyama I, Gao D, Tseng A, et al. 2011. SCF/Fbw7 regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction. *Nature* 471:104–9

Jeffers JR, Parganas E, Lee Y, Yang C, Wang J, et al. 2003. Puma is an essential mediator of p53-dependent and -independent apoptotic pathways. *Cancer Cell* 4:321–28

Ke FFS, Vanyai HK, Cowan AD, Delbridge ARD, Whitehead L, et al. 2018. Embryogenesis and adult life in the absence of intrinsic apoptosis effectors BAX, BAK, and BOK. *Cell* 173:1217–30.e17

Kelly GL, Grabow S, Glaser SP, Fitzsimmons L, Aubrey BJ, et al. 2014. Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in p53. *Genes Dev.* 28:58–70

Kelly PN, Grabow S, Delbridge ARD, Strasser A, Adams JM. 2011. Endogenous Bcl-xL is essential for Myc-driven lymphomagenesis in mice. *Blood* 118:6380–86

Kelly PN, Puthalakath H, Adams JM, Strasser A. 2007. Endogenous bcl-2 is not required for the development of Eμ-myc-induced B-cell lymphoma. *Blood* 109:4907–13

Konopleva M, Polleyea DA, Poduri J, Chyla B, Hogdal L, et al. 2016. Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia. *Cancer Discov.* 6:1106–17

Koss B, Morrison J, Percivalle RM, Singh H, Rehg JE, et al. 2013. Requirement for antiapoptotic MCL-1 in the survival of BCR-ABL B-lineage acute lymphoblastic leukemia. *Blood* 122:1587–98

Kotschy A, Slavik Z, Murray J, Davidson J, Maragno AL, et al. 2016. The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models. *Nature* 538:477–82

Kuroda J, Puthalakath H, Cragg MS, Kelly PN, Bouillet P, et al. 2006. Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic. *PNAS* 103:14907–12

Kuwana T, Bouchier-Hayes L, Chipuk JE, Bonzon C, Sullivan BA, et al. 2005. BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly. *Mol. Cell* 17:525–35

Le Gouill S, Podar K, Amiot M, Hideshima T, Chauhan D, et al. 2004. VEGF induces Mcl-1 up-regulation and protects multiple myeloma cells against apoptosis. *Blood* 104:2886–92

Lee EF, Harris TJ, Tran S, Evangelista M, Arunalanda S, et al. 2019. BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival. *Cell Death Dis.* 10:342

Letai AG. 2008. Diagnosing and exploiting cancer’s addiction to blocks in apoptosis. *Nat. Rev. Cancer* 8:121–32

Leverson JD, Zhang H, Chen J, Tahir SK, Phillips DC, et al. 2015. Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax). *Cell Death Dis.* 6:e1590

Lindsten T, Ross AJ, King A, Zong W, Rathmell JC, et al. 2000. The combined functions of proapoptotic Bcl-2 family members Bak and Bax are essential for normal development of multiple tissues. *Mol. Cell* 6:1389–99

Mason KD, Carpinelli MR, Fletcher JI, Collinge JE, Hilton AA, et al. 2007. Programmed anuclear cell death delimits platelet life span. *Cell* 128:1173–86

Merino D, Kelly GL, Lessene G, Wei AH, Roberts AW, Strasser A. 2018. BH3-mimetic drugs: blazing the trail for new cancer medicines. *Cancer Cell* 34:879–91

Motoyama N, Wang F, Roth KA, Sawa H, Nakayama K, et al. 1995. Massive cell death of immature hematopoietic cells and neurons in Bcl-x-deficient mice. *Science* 267:1506–10
Mott JL, Kobayashi S, Bronk SF, Gores GJ. 2007. mir-29 regulates Mcl-1 protein expression and apoptosis. Oncogene 26:6133–40

Moujalled DM, Pomilio G, Ghirau R, Ivey A, Salmon J, et al. 2019. Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia. Leukemia 33(4):905–17

Nangia V, Siddique FM, Caenepeel S, Timonina D, Bilton SJ, et al. 2018. Exploiting MCL1 dependency with combination MEK + MCL1 inhibitors leads to induction of apoptosis and tumor regression in KRAS-mutant non–small cell lung cancer. Cancer Discov. 8:1598–613

Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, et al. 2005. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435:677–81

Opferman JT, Iwasaki H, Ong CC, Suh H, Mizuno S, et al. 2005. Obligate role of anti-apoptotic MCL-1 in the survival of hematopoietic stem cells. Science 307:1101–4

Opferman JT, Letai A, Beard C, Soricinelli MD, Ong CC, Korsmeyer SJ. 2003. Development and maintenance of B and T lymphocytes requires anti-apoptotic MCL-1. Nature 426:671–76

Pan R, Hodgal LJ, Benito JM, Bucci D, Han L, et al. 2014. Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Discov. 4:362–75

Papatzimas JW, Gorobets E, Maity R, Muniyaiti ML, MacCallum JL, et al. 2019. From inhibition to degradation: targeting the anti-apoptotic protein myeloid cell leukemia 1 (MCL1). J. Med. Chem. 62:5522–40

Peperzak V, Vikstrom I, Walker J, Glaser SP, LePage M, et al. 2013. Mcl-1 is essential for the survival of plasma cells. Nat. Immunol. 14:290–97

Percivalle RM, Stewart DP, Koss B, Lynch J, Milasta S, et al. 2012. Anti-apoptotic MCL-1 localizes to the mitochondrial matrix and couples mitochondrial fusion to respiration. Nat. Cell Biol. 14:575–83

Print CG, Loveland KL, Gibson L, Meehan T, Stylianou A, et al. 1998. Apoptosis regulator Bcl-w is essential for spermatogenesis but appears otherwise redundant. PNAS 95:12424–31

Puthalakath H, O’Reilly LA, Gunn P, Lee L, Kelly PN, et al. 2007. ER stress triggers apoptosis by activating BH3-only protein Bim. Cell 129:1337–49

Rampino N, Yamamoto H, Ionov Y, Li Y, Sawai H, et al. 1997. Somatic frameshift mutations in the bax gene in colon cancers of the microsatellite mutator phenotype. Science 275:967–69

Ramsey HE, Fischer MA, Lee T, Gorska AE, Arrate MP, et al. 2018. A novel MCL1 inhibitor combined with venetoclax rescues venetoclax-resistant acute myelogenous leukemia. Cancer Discov. 8:1566–81

Rinkenberger JL, Horning S, Klocke B, Roth K, Korsmeyer SJ. 2000. Mcl-1 deficiency results in peri-implantation embryonic lethality. Genes Dev. 14:23–27

Roberts AW, Davids MS, Pagel JM, Kahl BS, Puvvada SD, et al. 2016. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N. Engl. J. Med. 374:311–22

Roberts AW, Seymour JF, Brown JR, Wierda WG, Kipps TJ, et al. 2012. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J. Clin. Oncol. 30:488–96

Schenk RL, Tuzlak S, Carrington EM, Zhan Y, Heinzel S, et al. 2017. Characterisation of mice lacking all functional isoforms of the pro-survival BCL-2 family member A1 reveals minor defects in the hematopoietic compartment. Cell Death Differ. 24:334–45

Schwickart M, Huang X, Lill JR, Liu J, Ferrando A, et al. 2010. Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival. Nature 463:103–7

Singh R, Letai A, Sarosiek K. 2019. Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins. Nat. Rev. Mol. Cell Biol. 20:175–93

Soucek L, Evan GI. 2010. The ups and downs of Myc biology. Curr. Opin. Genet. Dev. 20:91–95

Souers AJ, Leveson JD, Boghaert ER, Ackler SL, Catron ND, et al. 2013. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat. Med. 19:202–8

Spinner S, Crispatz G, Yi JH, Mункhbatar E, Mayer P, et al. 2016. Re-activation of mitochondrial apoptosis inhibits T-cell lymphoma survival and treatment resistance. Leukemia 30:1520–30

Strasser A, Harris AW, Bath ML, Cory S. 1990. Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2. Nature 348:331–33
Strasser A, Harris AW, Cory S. 1991. Bcl-2 transgene inhibits T cell death and perturbs thymic self-censorship. 
Cell 67:889–99
Strasser A, O’Connor L, Dixit VM. 2000. Apoptosis signaling. Annu. Rev. Biochem. 69:217–45
Tagawa H, Karnan S, Suzuki R, Matsuo K, Zhang X, et al. 2005. Genome-wide array-based CGH for mantle cell lymphoma: identification of homozygous deletions of the proapoptotic gene BIM. Oncogene 24:1348–58
Thomas LW, Lam C, Edwards SW. 2010. Mcl-1; the molecular regulation of protein function. FEBS Lett. 584:2981–89
Thomas RL, Roberts DJ, Kubli DA, Lee Y, Quinsay MN, et al. 2013. Loss of MCL-1 leads to impaired autophagy and rapid development of heart failure. Genes Dev. 27:1365–77
Tron AE, Belmonte MA, Adam A, Aquila BM, Boise LH, et al. 2018. Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia. Nat. Commun. 9:5341
Tsujimoto Y, Finger LR, Yunis J, Nowell PC, Croce CM. 1984. Cloning of the chromosome breakpoint of neoplastic B cells with the (14;18) chromosome translocation. Science 226:1097–99
Vaux DL, Cory S, Adams JM. 1988. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myb to immortalize pre-B cells. Nature 335:440–42
Veis DJ, Sorensen CM, Shutter JR, Korsmeyer SJ. 1993. Bcl-2-deficient mice demonstrate fulminant lymphoid apoptosis, polycystic kidneys, and hypopigmented hair. Cell 75:229–40
Vikstrom IB, Carotta S, Luethje K, Peperzak V, Jost PJ, et al. 2010. Mcl-1 is essential for germinal center formation and B cell memory. Science 330:1095–99
Vikstrom IB, Sloomp A, Carrington EM, Moesbergen LM, Chang C, et al. 2016. MCL-1 is required throughout B-cell development and its loss sensitizes specific B-cell subsets to inhibition of BCL-2 or BCL-XL. Cell Death Dis. 7:e2345
Villanova L, Careccia S, De Maria R, Fiori ME. 2018. Micro-economics of apoptosis in cancer: ncRNAs modulation of BCL-2 family members. Int. J. Mol. Sci. 19:958
Villunger A, Michalak EM, Coultas L, Mullauer F, Bock G, et al. 2003. p53- and drug-induced apoptotic responses mediated by BH3-only proteins Puma and Noxa. Science 302:1036–38
Vo TT, Ryan J, Carrasco R, Neuberg D, Rossi DJ, et al. 2012. Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML. Cell 151:344–55
Wagner KU, Claudio E, Rucker EB 3rd, Riedlinger G, Broussard C, et al. 2010. Conditional deletion of the Bcl-x gene from erythroid cells results in hemolytic anemia and profound splenomegaly. Development 127:4949–58
Wang JM, Lai MZ, Yang-Yen HF. 2003. Interleukin-3 stimulation of mcl-1 gene transcription involves activation of the PU.1 transcription factor through a p38 mitogen-activated protein kinase–dependent pathway. Mol. Cell. Biol. 23:1896–909
Wang X, Bathina M, Lynch J, Koss B, Calabrese C, et al. 2013. Deletion of MCL-1 causes lethal cardiac failure and mitochondrial dysfunction. Genes Dev. 27:1351–64
Warr MR, Acoca S, Liu Z, Germain M, Watson M, et al. 2005. BH3-ligand regulates access of MCL-1 to its E3 ligase. FEBS Lett. 579:5603–8
Wilson WH, O’Connor OA, Cauzeman MS, Lacasce AS, Gerecitano JF, et al. 2010. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol. 11:1149–59
Zantl N, Weirich G, Zall H, Seiffert BM, Fischer SF, et al. 2007. Frequent loss of expression of the pro-apoptotic protein Bim in renal cell carcinoma: evidence for contribution to apoptosis resistance. Oncogene 26:7038–48
Zhong Q, Gao W, Du F, Wang X. 2005. Mule/ARF-BP1, a BH3-only E3 ubiquitin ligase, catalyzes the polyubiquitination of Mcl-1 and regulates apoptosis. Cell 121:1085–95
Contents

AMP-Activated Protein Kinase: Friend or Foe in Cancer?
Diana Vara-Ciruelos, Madhumita Dandapani, and D. Grahame Hardie .......................... 1

Metabolism in the Tumor Microenvironment
Allison N. Lau and Matthew G. Vander Heiden ............................................................. 17

Mitophagy and Mitochondrial Dysfunction in Cancer
Kay F. Madeo .................................................................................................................... 41

Targeting MYC Proteins for Tumor Therapy
Elmar Wolf and Martin Eilers ............................................................................................. 61

Metabolic Drivers in Hereditary Cancer Syndromes
Marco Sciacovelli, Christina Schmidt, Eamonn R. Maher, and Christian Frezza ........... 77

Investigating Tumor Heterogeneity in Mouse Models
Tuomas Tammela and Julien Sage ..................................................................................... 99

Engineering T Cells to Treat Cancer: The Convergence of Immuno-Oncology and Synthetic Biology
Joseph H. Choe, Jasper Z. Williams, and Wendell A. Lim .................................................. 121

Lactate and Acidity in the Cancer Microenvironment
Scott K. Parks, Wolfgang Mueller-Klieser, and Jacques Pouysségur ............................... 141

Reactivation of Endogenous Retroelements in Cancer Development and Therapy
Charles A. Ishak and Daniel D. De Carvalho ................................................................. 159

WNT and β-Catenin in Cancer: Genes and Therapy
Rene Jackstadt, Michael Charles Hodder, and Owen James Sansom ............................... 177

The Epithelial-to-Mesenchymal Transition in Development and Cancer
Alexandre Francou and Kathryn V. Anderson .................................................................... 197

RNA Modifications in Cancer: Functions, Mechanisms, and Therapeutic Implications
Huilin Huang, Hengyou Weng, Xiaolan Deng, and Jianjun Chen ................................. 221
Is There a Clinical Future for IDO1 Inhibitors After the Failure of Epacadostat in Melanoma?
Benoit J. Van den Eynde, Nicolas van Baren, and Jean-François Baurain .......... 241

Deregulation of Chromosome Segregation and Cancer
Natalie L. Curtis, Gian Filippo Ruda, Paul Brennan, and Victor M. Bolanos-García ....................................................... 257

Acquired Resistance in Lung Cancer
Asmin Tulpule and Trever G. Bivona ........................................... 279

Toward Targeting Antiapoptotic MCL-1 for Cancer Therapy
Gemma L. Kelly and Andreas Strasser ........................................... 299

Nongenetic Mechanisms of Drug Resistance in Melanoma
Vito W. Rebecca and Meenhard Herlyn ........................................ 315

Biomarkers for Response to Immune Checkpoint Blockade
Shridar Ganesan and Janice Mehnert ........................................... 331

Immune-Based Approaches for the Treatment of Pediatric Malignancies
Kristopher R. Bosse, Robbie G. Majzner, Crystal L. Mackall, and John M. Maris ....................................................... 353

The Neural Regulation of Cancer
Shawn Gillespie and Michelle Monje ........................................... 371

Cancer-Associated Cachexia: A Systemic Consequence of Cancer Progression
Anup K. Biswas and Swarnali Acharyya ........................................ 391

The Pleiotropic Role of the KEAP1/NRF2 Pathway in Cancer
Warren L. Wu and Thales Papagiannakopoulos ................................ 413

The Role of Translation Control in Tumorigenesis and Its Therapeutic Implications
Yichen Xu and Davide Ruggero .................................................... 437

Regulatory T Cells in Cancer
George Plitas and Alexander Y. Rudensky ....................................... 459

Errata

An online log of corrections to Annual Review of Cancer Biology articles may be found at http://www.annualreviews.org/errata/cancerbio
